Oxidopamine - Toxicity
Research News and Information

Sunday, March 21, 2010

Reward-seeking and discrimination deficits displayed by hypodopaminergic mice are prevented in mice lacking dopamine D4 receptors.

30 Oct 2009 The dopamine D4 receptor (D4R) is predominantly expressed in the prefrontal cortex, a brain area that integrates motor, rewarding, and cognitive information. Because participation of D4Rs in executive learning is largely unknown, we challenged D4R ... Read more...

Serotonin 1B receptor stimulation reduces D1 receptor agonist-induced dyskinesia.

21 Sep 2009 Dopamine replacement therapy for the treatment of Parkinson's disease leads to deleterious abnormal involuntary movements (AIMs), known as L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia, which parallels enhanced striatal dopamine D1 ... Read more...

Neuroprotection in a 6-hydroxydopamine-lesioned Parkinson model using lactoferrin-modified nanoparticles.

30 Aug 2009 BACKGROUND: Nonviral gene therapy of chronic degenerative diseases such as Parkinson's disease (PD) is a great challenge as a result of the low tranfection efficiency of nonviral gene vectors. We previously constructed a lactoferrin (Lf)-modified ... Read more...

Latest indexed articles for 'Oxidopamine - Toxicity'

These are the very latest articles for this heading:

• Reward-seeking and discrimination deficits displayed by hypodopaminergic mice are prevented in mice lacking dopamine D4 receptors. 30 Oct 2009
• Serotonin 1B receptor stimulation reduces D1 receptor agonist-induced dyskinesia. 21 Sep 2009
• Neuroprotection in a 6-hydroxydopamine-lesioned Parkinson model using lactoferrin-modified nanoparticles. 30 Aug 2009
• Effects of early vs. late initiation of levodopa treatment in hemiparkinsonian rats. 25 Aug 2009
• Neocortical movement representations are reduced and reorganized following bilateral intrastriatal 6-hydroxydopamine infusion and dopamine type-2 receptor antagonism. 20 Aug 2009
• Reconstruction of the nigrostriatal dopamine pathway in the adult mouse brain. 8 Aug 2009
• Parkin deficiency disrupts calcium homeostasis by modulating phospholipase C signalling. Aug 2009
• Marked behavioral activation from inhibitory stimulation of locus coeruleus alpha1-adrenoceptors by a full agonist. 22 Jul 2009
• Bilateral high frequency stimulation of the subthalamic nucleus normalizes COX activity in the substantia nigra of Parkinsonian rats. 7 Jul 2009
• Investigation of neuroprotective effects of cyclooxygenase inhibitors in the 6-hydroxydopamine induced rat Parkinson model. 29 Jun 2009
• Retinal pigment epithelial cells secrete neurotrophic factors and synthesize dopamine: possible contribution to therapeutic effects of RPE cell transplantation in Parkinson's disease. 26 Jun 2009
• Ketogenic diet protects dopaminergic neurons against 6-OHDA neurotoxicity via up-regulating glutathione in a rat model of Parkinson's disease. 23 Jun 2009
• Chronic, systemic treatment with a metabotropic glutamate receptor 5 antagonist in 6-hydroxydopamine partially lesioned rats reverses abnormal firing of dopaminergic neurons. 19 Jun 2009
• Effects of dopamine depletion on network entropy in the external globus pallidus. 15 Jun 2009
• Dopamine depletion induces distinct compensatory gene expression changes in DARPP-32 signal transduction cascades of striatonigral and striatopallidal neurons. 25 May 2009
• Noradrenergic modulation of the motor response induced by long-term levodopa administration in Parkinsonian rats. 24 May 2009
• A role for medial prefrontal dopaminergic innervation in instrumental conditioning. 18 May 2009
• Nrf2 activators provide neuroprotection against 6-hydroxydopamine toxicity in rat organotypic nigrostriatal cocultures. 13 May 2009
• Neuroprotective effects of Astragaloside IV in 6-hydroxydopamine-treated primary nigral cell culture. 2 May 2009
• The CB(1) antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson's disease. May 2009

See a longer list of these articles.

Technical information about 'Oxidopamine'

Definition: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.

Chemical name: 1,2,4-Benzenetriol, 5-(2-aminoethyl)-

Registry Number: 1199-18-4

Descriptor UI: D016627

Alternative terms: Oxidopamine; 6-OHDA; 6-Hydroxydopamine; 6 Hydroxydopamine; Oxidopamine Hydrochloride; Hydrochloride, Oxidopamine; Oxidopamine Hydrobromide; Hydrobromide, Oxidopamine;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Sympatholytics; Adrenergic Agents;

Tree Number: D02.092.311.342.478.650;

Online Note: use OXIDOPAMINE (NM) to search 6-HYDROXYDOPAMINE (NM) 1980-91

History Note: 92; was 6-HYDROXYDOPAMINE (NM) 1981-91